STUDY OF NIVOLUMAB (BMS-936558) IN COMBINATION WITH GEMCITABINE/CISPLATIN, PEMETREXED/CISPLATIN, CARBOPLATIN/PACLITAXEL, BEVACIZUMAB MAINTENANCE, ERLOTINIB, IPILIMUMAB OR AS MONOTHERAPY IN SUBJECTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) (CHECKMATE 012):